New Abbott Test Available in Europe Provides Novel Tool to Aid Doctors in Evaluating Potential Heart Attacks

Wed Jan 9, 2013 7:00am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

Innovative test may help clinicians reduce time in diagnosing heart attacks and
assist in determining risk for those who may have future heart attacks
ABBOTT PARK, Ill.,  Jan. 9, 2013  /PRNewswire/ -- An estimated 17 million people
throughout the world die annually of cardiovascular diseases, specifically heart
attacks or strokes.1  Time is a critical factor in diagnosing and treating
people who may be having a potential heart attack. To aid physicians in
detecting heart attacks sooner, Abbott announced today CE Marking (Conformite
Europeenne) for the ARCHITECT  STAT  High Sensitive Troponin-I Assay.   

Diagnosing Potential Heart Attacks

The preferred biomarker used to identify suspected heart attacks is cardiac
troponin, a protein found in the heart muscle, because it can detect injury to
the heart.2  Many patients who visit the emergency room with chest pain
complaints and a suspected heart attack currently have blood samples drawn for
troponin tests upon admission, after 6 hours, and then potentially 12 hours
later before a diagnosis may be made.3  For patients who are having a heart
attack, the length of time to diagnosis is a crucial factor because the heart
muscle cells start to die after the heart stops receiving blood, and eventually,
almost all the affected parts of the heart could be irreversibly damaged.   

Abbott's new ARCHITECT  STAT  High Sensitive Troponin-I Assay can measure very
low levels of the protein, which allows doctors to evaluate whether or not
patients are having a heart attack within 2 to 4 hours.4  This faster evaluation
could allow doctors to reduce the time to diagnosis and treatment by several
hours when compared to standard troponin tests.

"The advantage of high sensitive troponin tests compared to current tests is
that clinicians may now more precisely confirm or exclude a heart attack much
sooner and with higher accuracy compared to contemporary tests," said Professor 
Stefan Blankenberg, Director of Cardiology at the University Heart Center of 
Hamburg, Germany. "This is important information for patient care because we can
pursue treatment if needed or avoid invasive therapy and discharge a patient

Determining Risk for Future Cardiovascular Events

Another concern for patients who have experienced symptoms of a heart attack or
who suffered from an actual attack is that they are at a higher risk for
experiencing a second cardiac event or heart attack within a few weeks or
months. Abbott's High Sensitive Troponin-I Assay also enables doctors to
determine if patients are at risk to suffer from cardiovascular events 30 days
and 90 days later.

"The sooner a patient can be diagnosed with a cardiac event, the faster a
patient can get the care he or she needs," said  Brian Blaser, executive vice
president, Diagnostics Products, Abbott. "Abbott's new high sensitive troponin
test is an innovative tool to help physicians diagnose more quickly, potentially
improving the way heart attacks are diagnosed for patients around the world."  

The new assay runs on Abbott's fully-automated ARCHITECT family of analyzers and
is available in CE marked and non-regulated countries, pending country

Intended Use

The ARCHITECT  STAT  High Sensitive Troponin-I assay is a chemiluminescent
microparticle immunoassay (CMIA) for the quantitative determination of cardiac
troponin I (cTnI) in human plasma and serum on the ARCHITECT  i  System with 
STAT  protocol capability. The cTnI values are used as an aid in the diagnosis
of myocardial infarction (MI) and to aid in the assessment of 30-day and 90-day
prognosis relative to all-cause mortality and major adverse cardiac events
(MACE) consisting of myocardial infarction, revascularization, and cardiac death
in patients who present with symptoms suggestive of acute coronary syndrome

About Cardiovascular Diseases

According to the World Health Organization (WHO), by 2030 almost 25 million
people will die from cardiovascular diseases, mainly from heart disease and
stroke. Cardiovascular diseases are projected to remain the single leading cause
of death.5

About Abbott Diagnostics

Abbott is a global leader in  in vitro  diagnostics and offers a broad range of
innovative instrument systems and tests for hospitals, reference labs, molecular
labs, blood banks, physician offices and clinics. With more than 22,000
customers in more than 100 countries, Abbott's diagnostic products offer
customers automation, convenience, bedside testing, cost effectiveness, and
flexibility. Abbott has helped transform the practice of medical diagnosis from
an art to a science through the company's commitment to improving patient care
and lowering costs.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life
through the development of products and technologies that span the breadth of
healthcare.  With a portfolio of leading, science-based offerings in
diagnostics, medical devices, nutritionals and branded generic pharmaceuticals,
Abbott serves people in more than 150 countries and employs approximately 70,000

Visit Abbott at  and connect with us on Twitter at @AbbottNews.

1 Cardiovascular Diseases Fact Sheet No 317. World Health Organization, 
September 2012. Web site:
2  Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of
myocardial infarction.  European Heart Journal.  2012; 33:2551-2567.
3  Thygesen K, Alpert JS, White HD et al.  Universal definition of myocardial
infarction.  European Heart Journal. 2007; 28:2525-38.
4  Abbott ARCHITECT  STAT  High Sensitive Troponin-I Product Insert (PI), 
January 2013.
5  Cardiovascular Diseases Fact Sheet No 317. World Health Organization, 
September 2012. Web site:

SOURCE  Abbott

Media, Darcy Ross, (847) 937-3655; or Jessica Masuga, (847) 935-0650, or
Financial, Tina Ventura, (847) 935-9390
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.